BR112022005578A2 - Composições e métodos para tratamento de doenças inflamatórias e imunes - Google Patents
Composições e métodos para tratamento de doenças inflamatórias e imunesInfo
- Publication number
- BR112022005578A2 BR112022005578A2 BR112022005578A BR112022005578A BR112022005578A2 BR 112022005578 A2 BR112022005578 A2 BR 112022005578A2 BR 112022005578 A BR112022005578 A BR 112022005578A BR 112022005578 A BR112022005578 A BR 112022005578A BR 112022005578 A2 BR112022005578 A2 BR 112022005578A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- treatment
- methods
- inflammatory
- immune diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Abstract
COMPOSIÇÕES E MÉTODOS PARA TRATAMENTO DE DOENÇAS INFLAMATÓRIAS E IMUNES. São fornecidos neste documento composições, métodos, estratégias, kits e artigos de fabricação que são úteis, inter alia, no tratamento ou na prevenção de doenças ou condições, tal como aquelas que podem estar associadas a inflamação, infecção, alergia, disfunção imune ou disbiose do microbioma intestinal. Em alguns aspectos, a invenção fornece uma combinação sinérgica de um prebiótico, por exemplo, uma mistura de oligossacarídeos de leite humano e uma cepa probiótica, tal como uma cepa capaz de internalizar e consumir os prebióticos, por exemplo, B. longum subsp.infantis.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962905256P | 2019-09-24 | 2019-09-24 | |
US202063027739P | 2020-05-20 | 2020-05-20 | |
US202063028743P | 2020-05-22 | 2020-05-22 | |
US202063053224P | 2020-07-17 | 2020-07-17 | |
PCT/US2020/052501 WO2021061991A1 (en) | 2019-09-24 | 2020-09-24 | Compositions and methods for treatment of inflammatory and immune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022005578A2 true BR112022005578A2 (pt) | 2022-09-20 |
Family
ID=72896070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022005578A BR112022005578A2 (pt) | 2019-09-24 | 2020-09-24 | Composições e métodos para tratamento de doenças inflamatórias e imunes |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230068960A1 (pt) |
EP (1) | EP4034143A1 (pt) |
JP (1) | JP2022548785A (pt) |
KR (1) | KR20220066904A (pt) |
CN (1) | CN114364389A (pt) |
AU (1) | AU2020354581A1 (pt) |
BR (1) | BR112022005578A2 (pt) |
CA (1) | CA3151145A1 (pt) |
IL (1) | IL291140A (pt) |
MX (1) | MX2022002949A (pt) |
TW (1) | TW202126317A (pt) |
WO (1) | WO2021061991A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111235132A (zh) * | 2019-12-23 | 2020-06-05 | 浙江工业大学 | 一种β-半乳糖苷酶、基因、工程菌及其应用 |
CN112458031B (zh) * | 2020-12-23 | 2022-04-29 | 江南大学 | 一株源自白酒酿造窖泥的产乳酸型己酸菌及其应用 |
CA3204530A1 (en) * | 2021-01-12 | 2022-07-21 | Gregory Mckenzie | Synbiotic treatment regimens |
AU2022294135A1 (en) * | 2021-06-18 | 2023-12-14 | Chr. Hansen A/S | Compositions for increasing resilience towards bacterial infections |
CN117858714A (zh) * | 2021-07-13 | 2024-04-09 | Ab-生物学有限公司 | 用于治疗肠道通透性增加的益生菌组合物 |
TW202340451A (zh) * | 2021-11-22 | 2023-10-16 | 香港中文大學 | 用於治療脫髮的益生菌組合物 |
US20230190834A1 (en) * | 2021-12-21 | 2023-06-22 | Solarea Bio, Inc. | Immunomodulatory compositions comprising microbial entities |
KR102616020B1 (ko) * | 2021-12-31 | 2023-12-22 | 매일유업 주식회사 | 모유 올리고당 혼합물을 유효성분으로 포함하는 장관면역 개선용, 장 염증 예방 또는 개선용 조성물 |
CN115029270B (zh) * | 2022-06-21 | 2023-11-28 | 江南大学 | 一株能够降低肠道促炎细胞因子的清酒乳杆菌及其应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8204879D0 (sv) | 1982-08-26 | 1982-08-26 | Haessle Ab | Novel chemical intermediates |
IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
SE9002043D0 (sv) | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
US5374730A (en) | 1993-11-04 | 1994-12-20 | Torcan Chemical Ltd. | Preparation of omeprazole and lansoprazole |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
US20020182243A1 (en) | 2001-05-14 | 2002-12-05 | Medo Elena Maria | Method of producing nutritional products from human milk tissue and compositions thereof |
WO2007035870A2 (en) | 2005-09-20 | 2007-03-29 | Prolacta Bioscience, Inc. | A method for testing milk |
EP2063722B1 (en) | 2006-08-30 | 2017-05-03 | Prolacta Bioscience, Inc. | Methods of obtaining sterile milk and compositions thereof |
US9084434B2 (en) | 2006-09-27 | 2015-07-21 | Little Calumet Holdings Llc | Probiotic oral dosage forms |
EP2099321B1 (en) | 2006-11-29 | 2017-04-19 | Prolacta Bioscience, Inc. | Human milk compositions and methods of making and using same |
WO2010065652A1 (en) | 2008-12-02 | 2010-06-10 | Prolacta Bioscience, Inc. | Human milk permeate compositions and methods of making and using same |
EP3335576A1 (en) * | 2010-12-31 | 2018-06-20 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
EP2479263B1 (en) | 2011-01-20 | 2013-11-27 | Jennewein Biotechnologie GmbH | Novel Fucosyltransferases and their applications |
US20140235850A1 (en) | 2011-09-30 | 2014-08-21 | Glycom A/S | Synthesis of hmo core structures |
US20150065702A1 (en) | 2012-03-20 | 2015-03-05 | Glycom A/S | Synthesis of the Trisaccharide 3-O-Fucosyllactose and Intermediates Thereof |
EP2859112A4 (en) | 2012-06-08 | 2015-10-28 | Glycom As | PROCESS FOR THE PREPARATION OF OLIGOSACCHARIDES AND OLIGOSACCHARIDE GLYCOSIDES BY FERMENTATION |
WO2013190530A1 (en) | 2012-06-22 | 2013-12-27 | Glycom A/S | Modified galactooligosaccharides |
EP2864344A4 (en) | 2012-06-22 | 2015-12-23 | Glycom As | GALACTOSYL GLYCOSYLATED DISACCHARIDES, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN CONSUMABLE PRODUCTS |
DK2868206T3 (en) * | 2012-07-05 | 2017-01-09 | Centro Nac De Tecnología Y Seguridad Alimentaria Laboratorio Del Ebro | Microparticles for encapsulating probiotics, manufacture and applications. |
WO2014135167A1 (en) | 2013-03-08 | 2014-09-12 | Glycom A/S | Purification of oligosaccaharides by reversible derivatization |
GB201306689D0 (en) | 2013-04-12 | 2013-05-29 | Glycom As | Synthesis of sialylated/fucosylated human milk oligosaccharides |
GB201306687D0 (en) | 2013-04-12 | 2013-05-29 | Glycom As | Synthesis of sialylated/fucosylated oligosaccharides |
US10364449B2 (en) | 2013-09-06 | 2019-07-30 | Glycom A/S | Fermentative production of oligosaccharides |
EP3572521A1 (en) | 2013-09-10 | 2019-11-27 | Jennewein Biotechnologie GmbH | Production of oligosaccharides |
EP2857410A1 (en) | 2013-10-04 | 2015-04-08 | Jennewein Biotechnologie GmbH | Process for purification of 2´-fucosyllactose using simulated moving bed chromatography |
EP2896628B1 (en) | 2014-01-20 | 2018-09-19 | Jennewein Biotechnologie GmbH | Process for efficient purification of neutral human milk oligosaccharides (HMOs) from microbial fermentation |
ES2715010T3 (es) | 2014-03-31 | 2019-05-31 | Jennewein Biotechnologie Gmbh | Fermentación total de oligosacáridos |
EP3161143A4 (en) | 2014-06-27 | 2018-02-21 | Glycom A/S | Oligosaccharide production |
WO2016183577A1 (en) * | 2015-05-14 | 2016-11-17 | Crestovo Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
EP3141610A1 (en) | 2015-09-12 | 2017-03-15 | Jennewein Biotechnologie GmbH | Production of human milk oligosaccharides in microbial hosts with engineered import / export |
WO2017101958A1 (en) | 2015-12-18 | 2017-06-22 | Glycom A/S | Fermentative production of oligosaccharides |
US20200046782A1 (en) * | 2016-03-11 | 2020-02-13 | Evolve Biosystems Inc. | Transient Commensal Microorganism for Improving Gut Health |
WO2018053535A1 (en) | 2016-09-19 | 2018-03-22 | Prolacta Bioscience, Inc. | Purified human milk oligosaccharides compositions |
DK3315610T3 (da) | 2016-10-29 | 2021-03-08 | Jennewein Biotechnologie Gmbh | Fremgangsmåde til fremstilling af fucosylerede oligosaccharider |
EP3425052A1 (en) | 2017-07-07 | 2019-01-09 | Jennewein Biotechnologie GmbH | Fucosyltransferases and their use in producing fucosylated oligosaccharides |
EP3450443A1 (en) | 2017-08-29 | 2019-03-06 | Jennewein Biotechnologie GmbH | Process for purifying sialylated oligosaccharides |
-
2020
- 2020-09-24 WO PCT/US2020/052501 patent/WO2021061991A1/en unknown
- 2020-09-24 JP JP2022518384A patent/JP2022548785A/ja active Pending
- 2020-09-24 CN CN202080063424.6A patent/CN114364389A/zh active Pending
- 2020-09-24 CA CA3151145A patent/CA3151145A1/en active Pending
- 2020-09-24 EP EP20792787.2A patent/EP4034143A1/en active Pending
- 2020-09-24 AU AU2020354581A patent/AU2020354581A1/en active Pending
- 2020-09-24 MX MX2022002949A patent/MX2022002949A/es unknown
- 2020-09-24 US US17/638,137 patent/US20230068960A1/en active Pending
- 2020-09-24 TW TW109133122A patent/TW202126317A/zh unknown
- 2020-09-24 KR KR1020227011619A patent/KR20220066904A/ko active Search and Examination
- 2020-09-24 BR BR112022005578A patent/BR112022005578A2/pt unknown
-
2022
- 2022-03-06 IL IL291140A patent/IL291140A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP4034143A1 (en) | 2022-08-03 |
JP2022548785A (ja) | 2022-11-21 |
IL291140A (en) | 2022-05-01 |
AU2020354581A1 (en) | 2022-03-03 |
CA3151145A1 (en) | 2021-04-01 |
KR20220066904A (ko) | 2022-05-24 |
US20230068960A1 (en) | 2023-03-02 |
WO2021061991A1 (en) | 2021-04-01 |
CN114364389A (zh) | 2022-04-15 |
MX2022002949A (es) | 2022-04-06 |
TW202126317A (zh) | 2021-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022005578A2 (pt) | Composições e métodos para tratamento de doenças inflamatórias e imunes | |
CO2017012829A2 (es) | Composiciones que comprenden cepas bacterianas | |
CY1124013T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
AR106768A1 (es) | Composiciones que comprenden cepas bacterianas | |
CY1122148T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
CY1122344T1 (el) | Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων | |
BR112015030389A2 (pt) | uso de i) uma fonte de proteína, ii) um prebiótico e iii) um probiótico para a fabricação de uma composição nutricional para o tratamento ou a prevenção de infecção em um indivíduo alérgico | |
CY1121473T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
CY1122184T1 (el) | Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη | |
CO2018010459A2 (es) | Composiciones que comprenden cepas bacterianas | |
CL2022000057A1 (es) | Métodos y productos para el tratamiento de trastornos gastrointestinales | |
EA201791702A1 (ru) | Терапевтические средства на основе гликанов и связанные с ними способы | |
BR112018005195A2 (pt) | lactobacillus plantarum lc27, composição farmacêutica para a prevenção ou tratamento de uma ou mais doenças, composição alimentícia para a prevenção ou tratamento de uma ou mais doenças, método de prevenção ou tratamento de uma ou mais doenças, e uso de uma composição que compreende lactobacillus plantarum lc27 | |
BR112017019468A2 (pt) | composições que metabolizam ou sequestram monômeros de açúcar livres e seus usos | |
BR112017018656A2 (pt) | bactéria modificada para tratar doenças que se beneficiam a partir de inflamação intestinal reduzida e/ou fortalecimento da barreira mucosa intestinal | |
BR112018015121A2 (pt) | cepa bacteriana da espécie faecalibacterium prausnitzii cncm i-4573 para o tratamento e a prevenção da inflamação gastrointestinal | |
BR112014016810A2 (pt) | composições e métodos para tratamento de distúrbios metabólicos | |
BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
BR112017002627A2 (pt) | prebióticos para reduzir o risco de obesidade no futuro | |
BR112022000280A2 (pt) | Cepa bacteriana de bifidobacterium bifidum, suas composições e usos relacionados | |
BR112017014107A2 (pt) | composição nutricional útil no tratamento de pacientes com ibd | |
AR102085A1 (es) | Composición nutricional para el entorno gastrointestinal para la provisión de un perfil metabólico y microbioma mejorados | |
BR112017018929A2 (pt) | uso de um probiotico e um peptídeo derivado de beta-lactoglobulina, composição, kit de peças, método para induzir tolerância oral, e/ou tratamento, prevenção ou redução do risco de ocorrência de alergia em um indivíduo | |
BR112017026241A2 (pt) | composições farmacêuticas e alimentícias para induzir a saciação e prolongar a saciedade em indivíduos que necessitem das mesmas |